## Ruth M Escalona

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5779665/publications.pdf

Version: 2024-02-01

759233 940533 16 651 12 16 citations h-index g-index papers 16 16 16 1058 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment. Frontiers in Oncology, 2021, 11, 796588.	2.8	12
2	TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells. BMC Cancer, 2020, 20, 960.	2.6	21
3	Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Seminars in Cancer Biology, 2018, 53, 265-281.	9.6	127
4	The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. International Journal of Molecular Sciences, 2018, 19, 450.	4.1	13
5	Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling. Scientific Reports, 2017, 7, 46312.	3.3	18
6	Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells. Scientific Reports, 2016, 6, 30061.	3.3	33
7	Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Frontiers in Oncology, 2014, 4, 75.	2.8	62
8	Effects of TGFbeta2 on Wild-Type and Tgfbr3 Knockout Mouse Fetal Testis1. Biology of Reproduction, 2013, 88, 66.	2.7	12
9	Fetal Testis Dysgenesis and Compromised Leydig Cell Function in Tgfbr3 (Betaglycan) Knockout Mice1. Biology of Reproduction, 2010, 82, 153-162.	2.7	63
10	Loss of Betaglycan Contributes to the Malignant Properties of Human Granulosa Tumor Cells. Molecular Endocrinology, 2009, 23, 539-548.	3.7	51
11	Reducing betaglycan expression by RNA interference (RNAi) attenuates inhibin bioactivity in L $\hat{I}^2$ T2 gonadotropes. Molecular and Cellular Endocrinology, 2009, 307, 149-156.	3.2	17
12	Transforming Growth Factor-Î <sup>2</sup> Blocks Inhibin Binding to Different Target Cell Types in a Context-Dependent Manner through Dual Mechanisms Involving Betaglycan. Endocrinology, 2007, 148, 5355-5368.	2.8	29
13	Inhibins Differentially Antagonize Activin and Bone Morphogenetic Protein Action in a Mouse Adrenocortical Cell Line. Endocrinology, 2006, 147, 3462-3471.	2.8	43
14	Labor-Associated Regulation of Prostaglandin E and F Synthesis and Action in the Ovine Amnion and Cervix. Journal of the Society for Gynecologic Investigation, 2006, 13, 19-24.	1.7	6
15	Prostaglandin E and F Receptor Expression and Myometrial Sensitivity at Labor Onset in the Sheep1. Biology of Reproduction, 2005, 72, 937-943.	2.7	17
16	Pituitary cell lines and their endocrine applications. Molecular and Cellular Endocrinology, 2004, 228, 1-21.	3.2	127